Humacyte Inc. (NASDAQ:HUMA) Q1 2023 Results Conference Call May 12, 2023 8:00 AM ET

Company Participants

Lauren Marek - LifeSci Advisors

Laura Niklason - Founder, President, CEO and Director

Dale Sander - CFO, Chief Corporate Development Officer and Treasurer

Conference Call Participants

Phil Dantoin - Piper Sandler

Ryan Zimmerman - BTIG

Joshua Jennings - TD Cowen

Suraj Kalia - Oppenheimer & Company

Bruce Jackson - Benchmark Company

Operator

Good morning, ladies and gentlemen, and welcome to the Humacyte First Quarter Results Conference Call. Currently, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. As a reminder, this conference call is being recorded.

I'll now turn the call over to Lauren Marek with LifeSci Advisors. Please go ahead.

Lauren Marek

Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC.

The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, except as required by law. Information presented on this call is contained in the press release we issued this morning and in our Form 10-Q, which after filing may be accessed from the Investors page of the Humacyte website.

Joining me on today's call from Humacyte are Dr. Laura Niklason, President and Chief Executive Officer; Dale Sander, Chief Financial Officer and Chief Corporate Development Officer and Dr. Heather Prichard, Chief Operating Officer. Dr. Niklason will provide a summary of the company's progress during the quarter and recent weeks, and Dale will review the company's financial results for the quarter ended March 31, 2023. Following their prepared remarks, the management team will be available for your questions.

I will now turn the call over to Dr. Niklason.

Laura Niklason

Thank you, Lauren. Good morning, everyone, and thank you for joining us for our first quarter 2023 financial results and business update call. This quarter was highly productive for Humacyte as we continued to advance our universally implantable bioengineered human tissue product candidate or the Human Acellular Vessel, or HAV, in multiple indications. We completed enrollment of our Phase III HAV trial and arteriovenous access in late March, and we're very close to completing enrollment of our Phase III trial in vascular trauma.